Guilhem Richard is a partner in Goodwin’s Life Sciences and Technology groups.
He specializes in capital markets and corporate finance particularly in the biotech, medtech and tech sectors. His experience includes a wide range of capital market transactions on Euronext and Nasdaq from equity (IPOs, dual listings, capital increases, private placements, block sales and ATM offerings…) to debt (high yield, OCEANE, ORA).
Guilhem also assists listed companies and their boards with their financing strategies and day-to-day issues relating to corporate and securities law and corporate governance.
Prior to joining Goodwin, Guilhem was a partner at Gide and previously worked in other international law firms.
Experience
Guilhem Richard’s recent transactions include advising:
- BNP Paribas and Van Lanschot Kempen on the capital increase by Argan for a total gross amount of €150 million.*
- Bryan Garnier & Co, Portzamparc BNP Paribas, Natixis and Gilbert Dupont on the capital increase by Waga Energy for a total gross amount of €52 million.*
- Leerink Partners, Stifel and Chardan on the capital increase by Sensorion for a total gross amount of €50.5 million.*
- Bryan Garnier & Co, Bryan Garnier Securities SAS and Jefferies on MedinCell's capital increase for institutional investors, via a private placement, for an estimated total gross amount of €24.3 million.*
- SVB Securities, LifeSci Capital et Bryan, Garnier & Co in connection with the successful pricing of an oversubscribed Abivax €130 million financing with high-quality U.S. and European biotech specialist investors, by way of a reserved capital increase.*
*Denotes experience prior to joining Goodwin.
- Jefferies LLC, Leerink Partners and Guggenheim on the capital increase by Nanobiotix reserved to category of investors, for an estimated total gross amount of $33.6 million.*
- Morgan Stanley, Leerink Partners, LifeSci Capital et Bryan Garnier & Co on the initial public offering on the Nasdaq Global Market of Abivax by way of a capital increase of approximately €223.3 million.*
- Jefferies LLC et Barclays Capital Inc. on Cellectis' capital increase for an estimated total gross amount of $25 million.*
- Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. on the capital increase by Valneva reserved to categories of investors, for an estimated total gross amount of €102.9 million.*
*Denotes experience prior to joining Goodwin.
Credentials
Education
Master
University of Paris I – Panthéon-Sorbonne
Master
Université Catholique de Louvain
Master
ESCP Business School
Admissions
Bars
- Paris, France
Recognition & Awards
Guilhem is recognized as a leader in his field by International and French preeminent, peer-reviewed publications.
- Ranked in Up and Coming in Capital Markets: Equity in the last edition of the Chambers Europe and Chambers Global guides
- Top Ranked Next Generation Partner in Capital Markets: Equity Capital Markets in the last edition of the Legal 500 EMEA guide
Publications
- Interview, “Guilhem Richard, un avocat qui veut du bien aux biotechs / Les cotations au Nasdaq n’ont plus de secret pour lui,” WanSquare, March 2023
- Co-Author (with Florent Bouyer), “Responsabilité du banquier introducteur pour rupture de la convention d'introduction en bourse,” Option Finance
- Co-Author (with Florent Bouyer), “Les émetteurs se rachètent auprès de leurs actionnaires,” Option Finance
- Co-Author (with Florent Bouyer), “Introduction en bourse et accès privilégié à l'offre : les viticulteurs champenois ont tracé le sillon,” Option Finance